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DOI 10.1016/j.chembiol.2010.12.005Blood clots may not look like much, just
tiny blobs of cells, lipids, and fibrin. But
clots can either save our lives or end our
lives, depending on when and where
they form. The process that brings about
clotting, thrombosis, is a highly regulated
cascade of protein interactions, with
thrombin running the show. Thrombin
helps regulate coagulation by living
a yin-yang life, acting both as a procoagu-
lant or an anticoagulant depending on
which protein it binds or doesn’t bind to.
Thrombin can even turn itself off in a nega-
tive feedback loop. These features give us
a natural ability to keep blood liquid
enough to flow through the circulatory
system and gelatinous enough to form
a clot so that we don’t bleed out. If
thrombin is activated under the wrong‘‘We are bringing closer to the market something that exploits
a natural pathway of anticoagulation in ways that do not produce
bleeding.’’ – Enrico Di Ceraconditions, though, clotting can lead to
debilitating or fatal consequences such
as heart attack, stroke, or deep vein
thrombosis.
To treat or prevent such conditions,
physicians use drugs called antithrom-
botics, which come in two categories de-
pending on their action: anticoagulants or
antiplatelets. Thrombin is also a primary
activator of platelets, tiny cells that help
blood clot.
Many medical conditions call for anti-
coagulant drugs, administered either
short or long term. People on dialysis
need anticoagulants so blood doesn’t
clot in the port that links the dialysis
machine to their blood supply. People
with atrial fibrillation are at higher risk of
stroke because a fast, irregular heartbeat
slows blood flow and thus raises the risk
of clotting. Orthopedic and cardiac
surgery can raise the risk of clotting in
the legs, called deep vein thrombosis.
Two of the oldest anticoagulants on the
market are warfarin (Coumadin) andheparin. Coumadin is given orally and
takes a few days to work; it’s commonly
used to prevent stroke associated with
atrial fibrillation. Heparin is injected and
works in minutes; it’s used in cardiac
bypass surgery and in orthopedic surgery
such as hip replacement.
Both drugs are tricky to dose because
the so-called therapeutic window is
narrow: too much and the drug causes
bleeding, too little and the drug won’t
work. Although Coumadin and heparin
are the most commonly used anticoagu-
lants, the dosing problem found with
them is true for any antithrombotic drug,
because anticoagulants disable hemo-
stasis, the system that keeps our blood
flowing inside the circulatory system and
plugs damaged vessels.Imagine clotting working like a two-
phase system: an injured blood vessel
brings a procoagulant response followed
quickly by an anticoagulant response. If
drugs boost the anticoagulant side of the
response, the procoagulant side is shut
down faster, so the net effect tilts toward
anticoagulation. That’s the down side of
the use of the current drugs, because all
drugs like Coumadin stop the procoagu-
lation side.
‘‘Until the safety of anticoagulation is
solved, we’ll have no solution for stroke
and heart attack, and these diseases will
remain the leading causes of death, says
Andras Gruber, M.D., a thrombin expert
at Oregon Health & Science University
School of Medicine. An anticoagulant
that can be administered to patients with
severe acute thrombotic diseases such
as heart attack and stroke, without the
risk of causing hemorrhage, would be so
significant as to revolutionize the treat-
ment of cardiovascular and cerebrovas-
cular diseases.’’Chemistry & Biology 17, December 22, 2010 ªIn 2010, two new oral anticoagulants hit
the market: dabigatran, which is a direct
thrombin inhibitor, and rivaroxaban,
which directly inhibits a protein called
factor Xa. In addition, many oral anticoag-
ulants are in the pipeline. All target either
thrombin or Xa, both late roadblocks in
the in the coagulation cascade that leads
to fibrin. Blocking fibrin formation would
stop clots, so these new drugs may mini-
mize bleeding risk.
Gruber has a different approach. In the
1990s, he wondered whether the part of
thrombin that clotted blood could be
disabled and the part that caused antico-
agulation could be kept. Such an engi-
neered molecule could work well as
a safe anticoagulant.
Developing engineered thrombin as
a therapeutic approach was not easy,
says Gruber, because injecting thrombin
at a little bit higher concentration than nor-
mally enters or resides in the blood stream
would cause potentially fatal clotting. The
most promising thrombin analog (mutant),
says Gruber, is one created by Enrico Di
Cera, chair of the Department of Bio-
chemistry and Molecular Biology at Saint
Louis University School of Medicine.
Di Cera and colleagues used protein
engineering to mutate the thrombin mole-
cule. By 2000, the group created
a thrombin with mutations at tryptophan
215 (W) and glutamate 217 (E); they
dubbed the W215A/E217A thrombin
mutant WE-thrombin. In a test tube, WE-
thrombin was able to activate protein C,
the natural anticlotting pathway that
controls and inhibits the coagulation. At
the same time, WE’s ability to clot blood
was reduced by several thousand-fold
(Cantwell and Di Cera, 2000).
By 2002, the researchers were able to
make enough WE-thrombin to test in
a baboon model. The mutant enzyme
activated protein C and had very little
activity against fibrinogen, the protein
that promotes clotting (Gruber et al.,
2002). More recently, Gruber and Di
Cera reported that low doses of WE acti-
vate protein C on the endothelial surface,2010 Elsevier Ltd All rights reserved 1267
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logical conditions. WE brought about an
anticoagulant response and no bleeding
was detected. This effect held true when
compared head-to-head with giving acti-
vated protein C directly and was also
safer than the administration of low
molecular weight heparins (Gruber et al.,
2007). ‘‘Importantly, no bleeding was de-
tected at doses of WE-thrombin that
produced significant antithrombotic
effects,’’ says Di Cera.
The group now has a new generation of
anticoagulant thrombin mutants pro-
duced by further protein engineering in
Di Cera’s lab. In this latest effort, the pro-
coagulant activity of the mutant can
abolish any possible side effects due to
fibrinogen clotting or platelet aggregation
(Marino et al., 2010). ‘‘With this research,
we optimized the mutant so that there is
no clotting at all. Furthermore, we gener-
ated a new mutant with exclusive pro-
thrombotic activity, thereby demon-
strating that the individual functions of
thrombin can be dissociated by replacing
a single amino acid in the protein,’’ says Di
Cera.
The financial stakes are high. World-
wide sales of anticoagulants are in the
tens of billions of dollars. In 2007, Gruber
founded a biotech company called Aro-
nora, LLC (named after Gruber’s son
and daughter, combined) (http://www.
aronorabio.com) to commercialize WE-
thrombin for various thrombotic disease
indications such as stroke and heart
attack. ‘‘I started Aronora because I was
convinced that this fundamentally new
method of anticoagulant treatment, acti-
vating protein C, was safe and, appar-
ently, also effective, and because I was
afraid that if I don’t do it, nobody will,’’
says Dr. Gruber.
For the first two years, Aronora, LLC
existed only on paper. Then in 2009, the
Company received notice of a Fast Track
SBIR award from the NIH NHLBI, which
allowed Gruber to hire a project manager.
Today, Aronora is still small; the company
has four employees (Gruber is not an
employee but he expects the company1268 Chemistry & Biology 17, December 22,to grow at a steady pace). ‘‘We’ve since
added other new technologies to our
product portfolio and have been pretty
successful to convince NIH that if they
do not help us to go after the big killers,
such as stroke, heart attack, sepsis,
nobody in the private sector will, because
these diseases are perceived as risky
investments or outright no-nos since
every drug in the field pretty much had
serious draw backs or even failed so
far,’’ says Gruber.
Marketing is several years away, even if
all goes well, and providing that financial
hurdles do not limit the effort. Until then,
the researchers are working to push WE-
thrombin through development as fast
and efficiently as they can, says Gruber.
‘‘Every day of delay can be translated to
lives. Of course, dealing with advanced,
acutely high mortality diseases such as
stroke and heart attack has a lot of risks,
as in these patients everything goes
south,’’ says Gruber.
‘‘I think it’s exciting,’’ says Nigel Mack-
man, an expert in the biochemistry coag-
ulation at the University of North Carolina
at Chapel Hill. ‘‘Clotting is much more
complicated than we appreciate and the
fact that two new drugs are coming on
the market says there’s room for more
anticoagulants in the market.’’ Several
drugs with different modes of actions
may be needed, says Mackman, as
thrombosis in different tissues induced
by different pathologies may have
a different event that starts them, and
new anticoagulants may not work for all
forms of thrombosis.
Mackman cautions that WE-thrombin
may have a drawback in that it’s boosting
the anticoagulant side via a natural
pathway. If a patient has any deficiencies
in one of the three proteins that make up
the protein C system, the WE-thrombin
may not work well. Likewise, in a situation
where the body is already making a lot of
thrombin, the WE may not be effective.
As an anticoagulant for surgery,
however, Mackman sees WE-thrombin
as a good drug. ‘‘You can put the drug on-
board to dampen that thrombin response2010 ª2010 Elsevier Ltd All rights reservedthat happens during surgery,’’ says
Mackman.
Meanwhile, Di Cera is working to scale
up production of WE-thrombin. He and
his colleagues found ways to make the
mutant efficiently in Escherichia coli; for
some reason, he says, this version of
WE-thrombin has a greater anticoagulant
effect than the mutant made in mamma-
lian cells. The group expects to file an
IND by 2012.
‘‘We are bringing closer to the market
something that exploits a natural pathway
of anticoagulation in ways that do not
produce bleeding. This is an innovative
and powerful tool to achieve anticoagula-
tion without disruption of the hemostatic
balance. Whether this is the ‘holy grail’
of anticoagulant therapy remains to be
seen.’’ says Di Cera. ‘‘Regardless of
what happens to WE-thrombin in the
clinics, the mutant has provided us with
a key reagent to dissect thrombin’s func-
tions and [with] unanticipated new infor-
mation about the molecular mechanisms
of activity and specificity of thrombin
and related proteases. What amazes me
is how much we still don’t know about
these enzymes.’’REFERENCES
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